T1	intervention 10 19	tamoxifen
T2	control 149 156	placebo
T3	eligibility 23 109	consecutive premenopausal women under surveillance in a high-risk breast cancer clinic
T4	average-age 497 520	between 33 and 46 years
T5	eligibility 521 593	at â‰¥17% lifetime risk of breast cancer and undergoing annual mammography
T6	No-of-participants 760 764	1279
T8	outcome 793 818	decided to take tamoxifen
T9	outcome 925 941	accept tamoxifen
T10	outcome 820 835	Women >40 years
T11	outcome 870 904	at higher non-BRCA-associated risk
T12	intervention-value 837 839	74
T13	intervention-participants 847 850	553
T14	intervention-value 852 857	13.4%
T15	intervention-value 943 946	129
T16	intervention-participants 954 958	1109
T17	intervention-value 960 965	11.6%
T7	intervention-value 781 784	136
T18	intervention-value 786 791	10.6%
